Multiple modes of action of myricetin in influenza A virus infection

Influenza A virus remains a major threat to public health worldwide after its first pandemic. Scientists keep searching novel anti‐influenza drugs, of which natural products present to be an important source. Myricetin, a natural flavonol compound, which exists in many edible plants, which has a wid...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2021-05, Vol.35 (5), p.2797-2806
Main Authors: Sang, Huiting, Huang, Yingna, Tian, Yuanxin, Liu, Miaomiao, Chen, Liurong, Li, Lin, Liu, Shuwen, Yang, Jie
Format: Article
Language:English
Subjects:
anti‐inflammatory
Binding
Biocompatibility
Cytokines
Cytotoxicity
Flavonols
Health risks
In vivo methods and tests
Inflammation
Influenza
Influenza A
influenza A virus
Molecular docking
Myricetin
Natural products
Pandemics
PB2 cap‐binding domain
Public health
Signal transduction
TLR3
TLR3 protein
Toll-like receptors
Toxicity
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Influenza A virus remains a major threat to public health worldwide after its first pandemic. Scientists keep searching novel anti‐influenza drugs, of which natural products present to be an important source. Myricetin, a natural flavonol compound, which exists in many edible plants, which has a wide range of biological activities, but its anti‐influenza A virus activity is ambiguous. This study aims to evaluate the anti‐influenza activity of myricetin and elucidate its underlying mechanism. Our results demonstrated that myricetin could significantly inhibit influenza A virus replication, reduce viral polymerase activity via selective inhibition of viral PB2 subunit, and the production of inflammatory cytokines by inhibiting TLR3 signaling pathway. The binding affinity analysis and the result of molecular docking revealed that myricetin interacted with the PB2 cap‐binding pocket of influenza A virus. The above results suggested myricetin could exhibit anti‐influenza virus activity with low cytotoxicity as well, and myricetin had low toxicity in BALB/c mice in vivo. Results from this study highlighted myricetin could be considered as a promising anti‐influenza virus agent with dual inhibition profile. Furthermore, the compound with similar structure would provide a new option for the development of novel inhibitors against influenza A virus.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.7025